NCT00408928View on ClinicalTrials.gov

Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2009

Conditions
Graft-versus-Host Disease
Interventions
DRUG

Bortezomib

Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT00408928 - Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease | Biotech Hunter | Biotech Hunter